Viking Thera adds most since 2024 after “clean” safety data for obesity drug
Viking Therapeutics surged by the largest margin since 2024 after releasing "clean" safety data for its obesity treatment.
Careful entry is under consideration, as the current price of $37.82 has surpassed the 20-day resistance of $34.99, while bearish signals—such as an RSI of 35.8, a moving average discrepancy, and a 6.3% decline over the past 7 days—are also taken into account.
Based on the current price, set the target price at the 20-day resistance level of $34.99 to take profit upon reaching it, and cut losses if the price breaks below the support level of $28.40.
The 14-day RSI stands at 35.8, nearing a mild oversold zone, while the moving averages are in a non-aligned state, trading volume is at 2.59 times the 20-day average, and the 7-day volatility recorded -6.3%.
We entered the position based on the strong positive catalyst of obesity treatment safety data, but failed to reach the projected 15.0% return, recording a -15.9% loss and receiving a FAILED rating. Despite recognizing clear bearish technical indicators—such as an RSI of 35.8, non-aligned moving averages, and a -6.3% decline over the trailing seven days—alongside the offering risk disclosed in the 424B5 filing, our reliance on short-term rebound momentum ultimately proved unable to withstand the downward pressure.
Through this trading review, I learned that even in the presence of favorable news, volatility must be managed more conservatively when technical indicators are inconsistent and the trend is downward. In future trades, I will more strictly verify whether the 20-day resistance line is broken and check the defensive strength of the support level. In particular, when compounded by the risk of equity dilution from large-scale offering disclosures, I will apply execution criteria to reduce the entry weight or hold off entirely.